Table 1.
Reported SLE cases with DAH treated by recombinant activated clotting Factor VII, extracorporeal membrane oxygenation or umbilical cord mesenchymal stem cells transplantation
| Author | Case (age/gender) | Received therapy | Outcome | |
|---|---|---|---|---|
| rFVIIa | Esper et al., 20143 | 37 F | MTPx3, RTX, rFVIIa | Survived |
| Alabed, 201442 | 37 F | MTPx3, CPM, rFVIIa | Survived | |
| Pathak et al., 201541 | 2 cases | Steroids, plasmapheresis, rFVIIa | Both Survived | |
| ECMO | Wang et al., 201830 | 3 cases | MTP, CPM, plasmapheresis, ECMO | All three died |
| Pais F et al., 201728 | 38 F | MTP, plasmapheresis, ECMO | Survived | |
| Pacheco Claudio et al., 201448 | 33 F | MTP, CPM, ECMO | Died | |
| 36 M | MTP, CPM, ECMO | Survived | ||
| Kimura et al., 201549 | 14 F | MTP, CPM, plasmapheresis, IVIG, ECMO | Survived | |
| Patel et al., 201450 | 28 F | MTP, CPM, RTX ECMO | Survived | |
| MSCT | Liang J et al., 201243 | 19 F | MTP, IVIG, UC-MSCT | Survived |
| Shi D et al., 201244 | 4 cases | Several regimens + UC-MSCT | All four improved |
F: female; M: male; rFVIIa: Recombinant activated clotting factor VII; MTP: methylprednisolone; RTX: rituximab; CPM: cyclophosphamide; ECMO: extracorporeal membrane oxygenation; IVIG: Intravenous immunoglobulin; UC-MSCT: umbilical cord mesenchymal stem cell transplantation.